NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.